Literature DB >> 19625477

Strain typing and antimicrobial resistance of fluoroquinolone-resistant Neisseria gonorrhoeae causing a California infection outbreak.

Sheldon R Morris1, Douglas F Moore, Paul B Hannah, Susan A Wang, Julia Wolfe, David L Trees, Gail Bolan, Heidi M Bauer.   

Abstract

Antimicrobial-resistant Neisseria gonorrhoeae is an emerging public health problem as a result of the alarming limitation in treatment options. We examined an outbreak in California of fluoroquinolone-resistant Neisseria gonorrhoeae (QRNG) by evaluation of a combination of routine isolates from the Gonococcal Isolate Surveillance Project and isolates collected by expanded surveillance performed between April 2000 and June 2002. QRNG isolates were characterized by two methods: (i) determination of a combination of antibiogram, auxotype, serovar, Lip type, and patterns of amino acid alteration in the quinolone resistance-determining region of GyrA and ParC (ASLGP) and (ii) pulsed-field gel electrophoresis (PFGE). Strain typing was used to describe the QRNG outbreak strains and the associated antimicrobial resistance profiles. Among 79 isolates that were completely characterized, we identified 20 different ASLGP strain types, and 2 of the types were considered to belong to outbreak strains that comprised 65% (51/79) of the isolates. By PFGE typing, there were 24 different strain types, and 4 of these were considered outbreak types and comprised 66% (52/79) of the isolates. The overall agreement between the typing methods in distinguishing outbreak strains and non-outbreak strains was 84% (66/79). The most common QRNG ASLGP strain type had chromosomally mediated resistance to penicillin and tetracycline and an azithromycin MIC of 0.5 microg/ml. The occurrence of an outbreak caused by QRNG strains that could fail to be eradicated by most antibiotic classes reinforces the serious problem with antimicrobial resistance in Neisseria gonorrhoeae that the public health system faces. Adherence to a regimen with the recommended antibiotics at the appropriate dose is critical, and monitoring for antimicrobial susceptibility needs to be actively maintained to adapt treatment guidelines appropriately.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625477      PMCID: PMC2738060          DOI: 10.1128/JCM.01001-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Using strain typing to characterise a fluoroquinolone-resistant Neisseria gonorrhoeae transmission network in southern California.

Authors:  S R Morris; J S Knapp; D F Moore; D L Trees; S A Wang; G Bolan; H M Bauer
Journal:  Sex Transm Infect       Date:  2008-03-13       Impact factor: 3.519

2.  Multidrug-resistant Neisseria gonorrhoeae.

Authors:  John Tapsall
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

Review 3.  Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies.

Authors:  Kimberly A Workowski; Stuart M Berman; John M Douglas
Journal:  Ann Intern Med       Date:  2008-04-15       Impact factor: 25.391

4.  Use of the neisserial lipoprotein (Lip) for subtyping Neisseria gonorrhoeae.

Authors:  D L Trees; A J Schultz; J S Knapp
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

5.  Fluoroquinolone-resistant Neisseria gonorrhoeae in Bali, Indonesia: 2004.

Authors:  Elizabeth A Donegan; Dewa N Wirawan; P Muliawan; Julius Schachter; Jeanne Moncada; Manhar Parekh; Joan S Knapp
Journal:  Sex Transm Dis       Date:  2006-10       Impact factor: 2.830

6.  Prevalence of and risk factors for quinolone-resistant Neisseria gonorrhoeae infection in Ontario.

Authors:  Kaede V Ota; Frances Jamieson; David N Fisman; Karen E Jones; Itamar E Tamari; Lai-King Ng; Lynn Towns; Prasad Rawte; Alessandro Di Prima; Tom Wong; Susan E Richardson
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

7.  Availability of cefixime 400 mg tablets--United States, April 2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-04-25       Impact factor: 17.586

8.  Increases in gonorrhea--eight western states, 2000--2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-03-16       Impact factor: 17.586

9.  Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance.

Authors:  Susan A Wang; Alesia B Harvey; Susan M Conner; Akbar A Zaidi; Joan S Knapp; William L H Whittington; Carlos del Rio; Franklyn N Judson; King K Holmes
Journal:  Ann Intern Med       Date:  2007-07-17       Impact factor: 25.391

10.  Threat to cefixime treatment for gonorrhea.

Authors:  Shigeaki Yokoi; Takashi Deguchi; Tomomi Ozawa; Mitsuru Yasuda; Shin-ichi Ito; Yasuaki Kubota; Masayoshi Tamaki; Shin-ichi Maeda
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

View more
  7 in total

Review 1.  Review and international recommendation of methods for typing neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology.

Authors:  Magnus Unemo; Jo-Anne R Dillon
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

2.  Prevalence of gonococcal and chlamydial infection in 2009 in 2 populations in a midwestern city.

Authors:  Abigail Norris Turner; Deanna Flynn; Merry Krempasky; Karen Fields; Wynette Collins; Melissa Ervin; Peggy Anderson; Tania Peterson; Mysheika LeMaile-Williams
Journal:  J Natl Med Assoc       Date:  2011-04       Impact factor: 1.798

Review 3.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

Review 4.  Genomic sequencing of Neisseria gonorrhoeae to respond to the urgent threat of antimicrobial-resistant gonorrhea.

Authors:  A Jeanine Abrams; David L Trees
Journal:  Pathog Dis       Date:  2017-06-01       Impact factor: 3.166

5.  TaqMan real-time quantitative PCR assay for detection of fluoroquinolone-resistant Neisseria gonorrhoeae.

Authors:  LiHong Zhao; ShuPing Zhao
Journal:  Curr Microbiol       Date:  2012-09-02       Impact factor: 2.188

6.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

Review 7.  On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.

Authors:  R Matthew Chico; Berkin B Hack; Melanie J Newport; Enesia Ngulube; Daniel Chandramohan
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.